Athanor Capital, LP Iovance Biotherapeutics, Inc. Transaction History

Athanor Capital, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$16.33 - $33.07 $197,413 - $399,783	-12,089 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$28.67 - $52.59 $668,785 - $1.23 Million	-23,327 Reduced 65.87%	12,089 $383,000
Q4 2020 Feb 16, 2021	BUY	$28.04 - $50.26 $993,064 - $1.78 Million	35,416 New	35,416 $1.64 Million
Q3 2020 Nov 16, 2020	SELL	$27.75 - $36.3 $1.02 Million - $1.34 Million	-36,895 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$27.21 - $41.0 $1 Million - $1.51 Million	36,895 New	36,895 $1.01 Million
Q1 2020 May 14, 2020	SELL	$19.54 - $38.85 $687,808 - $1.37 Million	-35,200 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$17.95 - $29.41 $68,210 - $111,758	3,800 Added 12.1%	35,200 $974,000
Q3 2019 Nov 14, 2019	BUY	$17.99 - $26.0 $564,886 - $816,400	31,400 New	31,400 $571,000

314

241M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.28B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Athanor Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Athanor Capital, LP with notifications on news.